Musculoskeletal/Rheumatology

Latest News

Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA

March 22nd 2023

Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.

FDA Approves Kevzara for Inflammatory Rheumatic Disease
FDA Approves Kevzara for Inflammatory Rheumatic Disease

March 1st 2023

 Will the Biosimilar Amjevita Lower Costs?
Will the Biosimilar Amjevita Lower Costs?

February 2nd 2023

First Humira Biosimilar is Now Available
First Humira Biosimilar is Now Available

January 31st 2023

Prime to Cover Biosimilars Alongside Humira
Prime to Cover Biosimilars Alongside Humira

December 16th 2022

More News

© 2023 MJH Life Sciences

All rights reserved.